Jenisch Jan Philipp
Known title: Chairman & CEOCIK: 0002068104
Jenisch Jan Philipp's purchase track record
How the stock did after each of Jenisch Jan Philipp's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 5 since August 8, 2025
Stock higher 6 months later
67%
3 months: 50%
Median 6-month return
+4.3%
3 months: -0.5%
Beat the S&P 500
33%
median -1.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/2/2026 | AMRZ | $1.27M | pending | pending | — |
| 5/15/2026 | AMRZ | $2.35M | -4.7% | pending | — |
| 3/6/2026 | AMRZ | $3.48M | -6.9% | -23.9% | +14.5% |
| 10/30/2025 | AMRZ | $5.80M | +4.2% | +4.3% | +5.7% |
| 8/8/2025 | AMRZ | $51.79M | +3.7% | +22.5% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMRZ | ▲ Buy | Open Market | 10,000 | $424K | 9/2/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $42K | 9/2/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 2,000 | $85K | 9/2/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 2,000 | $85K | 9/2/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 15,000 | $638K | 9/2/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 3,001 | $149K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 7,000 | $348K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,360 | $66K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 2,000 | $97K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,640 | $80K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $49K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 3,000 | $150K | 5/19/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 7,000 | $344K | 5/15/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 13,417 | $667K | 5/15/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 8,000 | $397K | 5/15/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 60,000 | $3.5M | 3/6/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 138,582 | $0 | 2/27/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 55,000 | $2.9M | 10/30/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 55,000 | $2.9M | 10/30/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 340,000 | $16.3M | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 180,000 | $8.6M | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 3,723 | $177K | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 21,277 | $1.0M | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 50,000 | $2.4M | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 10,000 | $463K | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 268 | $12K | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 186 | $9K | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 99,546 | $4.6M | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 100,000 | $4.6M | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 60,000 | $2.9M | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 100,000 | $4.6M | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 40,000 | $1.9M | 8/8/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 90,000 | $4.2M | 8/8/2025 | View on chart |
| AMRZ | ▼ Sell | Other | 805,000 | $0 | 6/23/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JP Morgan cuts Amrize price target to $48, maintains Neutral
JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.
JP Morgan cuts Amrize price target to $48, maintains Neutral. JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.